Sign In
Buy MNMD
$20.69
+0 (+0%)
At Close: Jun 18, 2026
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
12:31pm, Tuesday, 18'th Jun 2024
As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuat
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
10:40am, Friday, 14'th Jun 2024
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?
10:46am, Wednesday, 29'th May 2024
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
MindMed to Participate in June Conferences
07:00am, Tuesday, 28'th May 2024
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to
The Time Traveler's Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034
03:41pm, Thursday, 23'rd May 2024
Imagine you could go back in time to find last decade's long-term stocks to buy. Nvidia (NASDAQ: NVDA ) returned nearly 20,000% growth since 2014.
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
12:15pm, Thursday, 23'rd May 2024
Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through
Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May
11:00am, Friday, 10'th May 2024
The stock market continues to question whether a large cap dominance — especially that from The Magnificent Seven — is indeed the best way to invest. While investing in large cap firms is undoubte
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
06:49am, Thursday, 09'th May 2024
Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and t
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to
The Top 3 Small-Cap Stocks to Buy in April 2024
03:00pm, Thursday, 25'th Apr 2024
Higher interest rates, pricier debt and an overemphasis on mega-caps over the past year mean that top small-cap stocks have played second fiddle to big-name giants like Nvidia (NASDAQ: NVDA ). But tid
MindMed to Present at Upcoming May Medical Conferences
07:00am, Thursday, 25'th Apr 2024
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates t
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
05:37am, Thursday, 25'th Apr 2024
Mind Medicine has an exciting treatment option for generalized anxiety disorder -- MM120. In clinical trials, MM120 reduced anxiety in patients after just a single dose.
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why
08:01am, Monday, 08'th Apr 2024
MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
12:43pm, Thursday, 04'th Apr 2024
Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder. End-of-phase 2 meeting with the FDA for
MindMed to Present at Upcoming April Medical Conferences
07:00am, Tuesday, 02'nd Apr 2024
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel
